RecruitingPhase 1Phase 2NCT06527495
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Clinical Pharmacogenetic Study of the Efficacy and Safety of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Sponsor
Assiut University
Enrollment
150 participants
Start Date
Jan 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria3
- Age of all studied subjects ≥ 18 years old
- All patients with hepatocellular carcinoma will be included in group I.
- Patients not treated with systemic TKIs
Exclusion Criteria8
- Patients presented with liver tumors other than HCC.
- Patients with Child-Pugh grade C for liver function.
- Patients with other malignancies.
- Patients with chronic inflammatory disorders.
- Patients with severe organ dysfunction such as heart, lung, and kidney.
- Patients who cannot tolerate or are allergic to sorafenib.
- Patients with severe coagulation dysfunction were uncorrectable.
- Age less than 18 years old.
Interventions
DRUGSorafenib
Sorafenib Tablets (200 -400 mg) twice daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06527495
Related Trials
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
NCT056298451 location
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
NCT054683592 locations
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
NCT0552895214 locations
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT0679611410 locations